Darolutamide Approved for Metastatic Castration-Sensitive Prostate Cancer
Expert Perspectives · Lyn Brook · 2025-06-05
The FDA has granted approval to darolutamide (Nubeqa®, Bayer Healthcare Pharmaceuticals Inc.) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). This approval expands darolutamide’s indications, now including use as monotherapy for mCSPC. Darolutamide was previously approved in combination with docetaxel for this patient population.
Why This Approval Matters
The approval of darolutamide for mCSPC provides clinicians with an additional, well-tolerated androgen receptor inhibitor option for patients with newly diagnosed metastatic disease. This decision is based on robust evidence demonstrating significant improvement in radiographic progression-free survival (rPFS), supporting darolutamide’s role as a standard of care in this setting. The availability of darolutamide as a monotherapy offers flexibility in treatment planning and may benefit patients who are not candidates for combination chemotherapy.
Breaking Down the ARANOTE Trial
The efficacy and safety of darolutamide were evaluated in the ARANOTE trial (NCT04736199), a 2:1 randomized, double-blind, placebo-controlled study enrolling 669 patients with mCSPC. Eligible patients received either darolutamide or placebo, in addition to a gonadotropin-releasing hormone (GnRH) analog or following prior bilateral orchiectomy. The primary end point was radiographic rPFS, with overall survival (OS) as a key secondary end point.
Results from the ARANOTE trial demonstrated a statistically significant improvement in rPFS for patients receiving darolutamide. Median rPFS was not reached in the darolutamide arm, compared to 25 months in the placebo arm. At the time of final analysis, there was no statistically significant difference in OS.
Managing Adverse Events
The adverse event profile observed with darolutamide in ARANOTE as a single agent was consistent with prior experience. Clinicians should be aware of important warnings and precautions, including the risk of ischemic heart disease, seizure, and embryo-fetal toxicity.
Clinical Implications and Future Outlook
“These results confirm the efficacy and tolerability of darolutamide plus androgen-deprivation therapy in patients with mHSPC, demonstrating clinically and statistically significant improvement in rPFS and a favorable safety profile consistent with prior phase 3 darolutamide trials,” concluded Fred Saad, MD, FRCS, the Director of Prostate Cancer Research at the Montreal Cancer Institute, and colleagues, in their published results of the ARANOTE trial.
Dosing and Administration
The recommended dose of darolutamide is 600 mg as two 300 mg tablets, taken orally, twice daily, with food. Treatment should continue until disease progression or unacceptable toxicity.